PharmAla Biotech To Supply MDMA For Harvard’s Maclean Hospital Clinical Trial
PharmAla Biotech Holdings Inc. (OTC:MDXXF) announced it has agreed to supply its LaNeo MDMA for a clinical trial at Harvard’s Maclean Hospital, a world-leading institution in neuroscience and psychiatric research. This agreement marks a significant step for PharmAla as it continues to expand its role in supporting MDMA-based clinical research across the U.S. The company’s CEO, Nicholas …